Hyperhomocyst(e)inemia and thrombophilia

Archives of Pathology and Laboratory Medicine

Volumn 126, Issue 11, 2002, Pages 1367-1375

  Key, Nigel S ^a   McGlennen, Ronald C ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; HYDROXOCOBALAMIN; PYRIDOXINE;

ARTERY THROMBOSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE MARKER; ENDOTHELIUM; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERHOMOCYSTEINEMIA; RELIABILITY; RISK FACTOR; SMOOTH MUSCLE FIBER; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

BLOOD COAGULATION TESTS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; PRACTICE GUIDELINES; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0036881491     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (72)

1. Fodinger M, Buchmayer H, Sunder-Plassmann G. Molecular genetics of homocysteine metabolism. Miner Electrolyte Metab. 1999;25:269-278.
2. Hanson NQ, Aras O, Yang F, Tsai MY. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem. 2001;47:661-666.
3. Rozen R. Genetic modulation of homocysteinemia. Semin Thromb Hemost. 2000;26:255-261.
4. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. New York, NY: McGraw-Hill; 1995:1279.
5. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995; 274:1049-1057.
6. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997; 277:1775-1781.
7. den Heiler M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 1998;80:874-877.
8. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thrombolic disease. Arch Int Med. 1998;158:2101-2106.
9. Egerton W, Silberberg J, Crooks R, Ray C, Xie L, Dudman N. Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am J Cardiol. 1996; 77:759-761.
10. Lindgren A, Brattstrom L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke. 1995;26:795-800.
11. Tsai AW, Cushman M, Tsai MY, et al. Serum homocysteine, methylene tetrahydrofolate reductase (MTHFR) C677T genotype, and risk of venous thromboembolism: the LITE study. Thromb Haemost. 2001;85(suppl):324a.
12. Folsom AR, Nieto J, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1998;98:204-210.
13. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile: the Hordaland Homocysteine Study. JAMA. 1995;275:1526-1533.
14. Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg IH. The kidney and homocysteine metabolism. J Am Soc Nephrol. 2001;12:2181-2189.
15. Selhub J, Jacques PF, Wilson PW. Vitamin status and intake as determinants of hyperhomocysteinemia in elderly patients. JAMA. 1993;270:2693-2698.
16. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA. 1999;281:1817-1821.
17. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Int Med. 1999;131:363-375.
18. Meleady R, Graham I. Plasma homocysteine as a cardiovascular risk factor: causal, consequential, or of no consequence? Nutr Rev. 1999;57:299-305.
19. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk. 1998; 5:229-232.
20. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-236.
21. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation. 1997;95:1777-1782.
22. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 1996;348:1120-1124.
23. Cattaneo M, Zighetti ML, Turner RM, et al. Fasting plasma homocysteine levels do not predict the occurrence of deep vein thrombosis after elective hip replacement surgery. Neth J Med. 1998;52(suppl):S21.
24. Eichinger S, Stumpfien A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost. 1998;80:566-569.
25. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common metriylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation. 1998;98:2520-2526.
26. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost. 1999;81:165-176.
27. Cattaneo M, Tsai MY, Bucciarelli P, et al. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506). Arterioscler Thromb Vasc Biol. 1997;17:1662-1666.
28. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine. N Engl J Med. 2001;345:1593-1600.
29. Willems HP, den Heijer M, Bos GM. Homocysteine and venous thrombosis: outline of a vitamin intervention trial. Semin Thromb Hemost. 2000;26:297-304.
30. Ross R. Atherosclerosis: an inflammatory disease. N Engl Med. 1999;340:115-126.
31. Lentz SR, Sobey CG, Piegors DJ, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 1996;98:24-29.
32. Bellamy MF, McDowell IFW, Ramsey MW, et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation. 1998;98:1848-1852.
33. Jakubowski H, Zhang L, Bardeguez A, Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res. 2000;87:45-54.
34. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 1986;77:1909-1916.
35. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 1991; 88:1906-1914.
36. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 1990;75:895-901.
37. Hajjar KA, Mauri L, Jacovina AT, et al. Tissue plasminogen activator binding to the annexin II tail domain: direct modulation by homocysteine. J Biol Chem. 1998;273:9987-9993.
38. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest. 1993;92:1381-1386.
39. Fryer RH, Wilson BD, Gubler DB, et al. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb. 1993;13:1327-1333.
40. Hofmann MA, Lalla E, Lu Y, et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest. 2001;107:675-683.
41. Cattaneo M, Franchi F, Zighetti ML, et al. Plasma levels of activated protein C in healthy subjects and patients with previous venous thromboembolism: relationship with plasma homocysteine levels. Arterioscler Thromb Vasc Biol 1998; 18:1371-1375.
42. Tsai JC, Wang H, Perrella MA, et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest. 1996;97:146-153.
43. Khajuria A, Houston DS. Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis. Blood. 2000;96:966-972.
44. Di Minno G, Davi G, Margaglione M. Abnormally high thromboxane biosynthesis in homozygous homocystinuria: evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest. 1993;92:1400-1406.
45. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J. 1997;11:1157-1168.
46. Undas A, Williams EB, Butenas S, Orfeo T, Mann KG. Homocysteine inhibits inactivation of factor Va by activated protein C. J Biol Chem. 2001;276:4389-4397.
47. Fokkema MR, Weijer JM, Dijck-Brouwer DA, van Doormaal JJ, Muskiet FA. Influence of vitamin-optimized plasma homocysteine cutoff values on the prevalence of hyperhomocysteinemia in healthy adults. Clin Chem. 2001;47:1001-1007.
48. Bostom AG, Jacques PF, Nadeau MR, Williams RR, Ellison RC, Selhub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from The NHLBI Family Heart Study. Atherosclerosis. 1995;116:147-151.
49. Willems HP, Bos GM, Gerrits WB, den Heiler M, Vloet S, Blom HJ. Acidic citrate stabilizes blood samples for assay of total homocysteine. Clin Chem. 1998; 44:342-345.
50. Willems HP, Bos GM, Gerrits WB, den Heijer M, Vloet S, Blom HJ. Acidic citrate stabilizes blood samples for assay of total homocysteine. Clin Chem. 1998; 44:342-345.
51. Salazar JF, Herbeth B, Siest G, Leroy P. Stability of blood homocysteine and other thiols: EDTA or acidic citrate? Chin Chem. 1999:45;2016-2019.
52. Ubbink JB, Hayward Vermaak WJ, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr. 1991;565:441-446.
53. Jacobsen DW, Gatautis VJ, Green R, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentration in healthy subjects. Clin Chem. 1994;40:873-881.
54. Pfeiffer CM, Huff DL, Smith SJ, Miller DT, Gunter EW. Comparison of plasma total homocysteine measurements in 14 laboratories: an international study. Clin Chem. 1999;45:1261-1268.
55. Tripodi A, Chantarangkul V, Lombardi R, Lecchi A, Mannucci PM, Cattaneo M. Multicenter study of homocysteine measurement: performance characteristics of different methods, influence of standards on interlaboratory agreement of results. Thromb Haemost. 2001;85:291-295.
56. Froost P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
57. Tsai MY, Hanson NQ, Bignell MK, Schwichtenberg KA. Simultaneous detection and screening of T833C and G919A mutations of the cystathionine beta-synthase gene by single-strand conformational polymorphism. Clin Biochem. 1996;29:473-477.
58. Tsai MY, Garg U, Key NS, Hanson NQ, Suh A, Schwichtenberg K. Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria. Atherosclerosis. 1996;122:69-77.
59. Tsai MY, Bignell M, Schwichtenberg K, Hanson NQ. High prevalence of a mutation in the cystathionine beta-synthase gene. Am J Hum Genet. 1996;59:1262-1267.
60. Tsai MY, Bignell M, Yang F, Welge BG, Graham KJ, Hanson NQ. Polygenic influence on plasma homocysteine: association of two prevalent mutations, the 844ins68 of cystathionine beta-synthase and A(2756)G of methionine synthase, with lowered plasma homocysteine levels. Atherosclerosis. 2000; 149:131-137.
61. Reiner AP, Siscovik DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost. 2001;85:584-595.
62. Neuhouser ML, Beresford SA. Folic acid: are current fortification levels adequate? Nutrition. 2001;17:868-872.
63. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism: Duration of Anticoagulation Study Group. N Engl J Med. 1995;332:1661-1665.
64. van der Griend R, Haas FJ, Duran M, Biesma DH, Meuwissen OJ, Banga J-D. Methionine loading test is necessary for detection of hyperhomocysteinemia. J Lab Clin Med. 1998;132:67-72.
65. Bostom AG, Roubenoff R, Dellaripa P, et al. Validation of abbreviated oral methionine-loading test. Clin Chem. 1995;6:948-949.
66. Cattaneo M, Martinelli J, Mannucci PM. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;335:974-975; discussion, 975-976.
67. Fermo I, Viganó D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Int Med. 1995;123:747-753.
68. Bos GM, den Heijer M. Hyperhomocysteinemia and venous thrombosis. Semin Thromb Hemost. 1998;24:387-391.
69. van der Griend R, Biesma DH, Banga JD. Clinical relevance of the methionine loading test for assessment of hyperhomocysteinaemia. Neth J Med. 2000;57:174-175.
70. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ. 1998;316:894-898.
71. Key NS. Hyperhomocyst(e)inemia. Curr Treat Options Cardiovasc Med. 2000;2:65-72.
72. Olson JD. College of American Pathologists Consensus Conference XXXVI: Diagnostic Issues in Thrombophilia: introduction and general considerations. Arch Pathol Lab Med. 2002;126:1277-1280.